GSK: £1bn investment in R&D over 10 years

(CercleFinance.com) - GSK today announced a £1 billion investment over ten years in infectious disease research and development.


Research will focus on new vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (via ViiV Healthcare), neglected tropical diseases (NTDs) and antimicrobial resistance (AMR), which continue to have a devastating impact on the most vulnerable.

In addition to this investment, GSK also announced significant new investments in global health. In particular, the company confirmed its commitment to provide albendazole, through the largest ever drug donation, until lymphatic filariasis and soil-borne helminthiasis morbidity are eliminated as a public health problem everywhere.

GSK also confirmed that it is doubling production of its AS01 adjuvant for use in the RTS,S malaria vaccine to help meet the projected demand for the vaccine over the medium term.


Copyright (c) 2022 CercleFinance.com. All rights reserved.